Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

NANOTESTS · Fabrication and development of nanotoxicology-test bacterial arrays for the investigation of antibiotics against multi drug-resistant bacteria

FP7Status: CLOSED1 March 201228 February 2015EU funding €223,670

Bacterial resistance to antibiotics is one of medicine's most vexing challenges. Most antibiotics initially work really well, killing more than 99.9% of microbes they target. But through mutation and the selection pressure exerted by the antibiotic, a few inevitably manage to survive, and flourish as antibiotic-resistant strains. Hence, new strategies to design antibiotic to combat drug-resistant bacteria are required. Many drug delivery systems based on nanomaterials have been developed during the last decade, being the toxicology of these materials into single bacteria still not thoroughly evaluated due to the lack of reliable techniques to confine individual microbes. Prof. Whitesides' group in Harvard University (USA) is undoubtedly a world leader in this area, as it has a high international profile earned through many key contributions about novel nanofabrication methods for microbiological applications during the last 20 years. Prof. Miranda and Prof. Carrascosa (both from IMDEA Nanoscience-Spain) are the leaders of research groups working in collaboration for (i) the development of novel antibiotic strategies based on drug delivery nano-systems and (ii) biophysical aspects of cell mechanics, self-assembly properties of organic heterostructures and supramolecular nanomachines. The time is ripe to integrate the various strategies developed by Prof. Whitesides’ group to confine single living bacteria with the novel strategies for drug delivery that are being developed at IMDEA Nanoscience-Spain.The aim of the present OIF includes consolidating IMDEA expertise in the toxicological effect of nanoparticle based drug carriers into individual bacteria in order to develop a novel set of antibiotics for treatment of multi drug-resistant bacteria and to contribute to fundamental questions about bacterial biology, such as cell wall biophysics, chemical bonding and DNA conformational dynamics.""

Consortium · 1 organisation

coordinator

FUNDACION IMDEA NANOCIENCIA

ES · €223,670

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.